Tes Pharma Presents Results on TESP-0401 in the Adenine-Induced model of Chronic Kidney Disease at the European Renal Association (ERA) Congress 2026
Solomeo-Corciano (PG), Italy, May 29, 2026 – Tes Pharma, a biopharmaceutical company focused on developing first-in-class therapeutics for high unmet medical needs in renal diseases, announced today that a poster presentation on the Company’s clinical candidate TESP-0401 will be delivered at the 63rd ERA Congress, taking place June 3–6, 2026, in Glasgow, Scotland, UK.
“We are excited to present the results of our latest research in chronic kidney disease (CKD) at the 63rd ERA Congress,” said Andrea Pellacani, Chief Medical Officer at Tes Pharma. “These data validate the scientific rationale of targeting the ACMSD enzyme to rescue mitochondrial dysfunction in the kidney and, importantly, expand the therapeutic potential of TESP-0401 for CKD, representing a key milestone for our growth. Our investigation supports the potential of targeting the de novo NAD⁺ biosynthesis through ACMSD inhibition as a differentiated strategy to treat renal diseases and strengthens the positioning of TESP‑0401 as a first‑in‑class candidate addressing areas of high unmet medical need.”
Title: TESP-0401 Provides Protection Against Renal Fibrosis in Adenine-Induced Chronic Kidney Disease
Session Title: Chronic Kidney Disease
Oral Presentation Date/Time: Friday, June 5, 2026, at 05:22 PM by: Francesca De Franco, PhD, Tes Pharma.
About TESP-0401
TESP‑0401 is a first‑in‑class ACMSD inhibitor that restores NAD⁺ levels by enhancing its de novo biosynthesis. Dysregulation of this pathway, and the resulting decline in NAD⁺ levels, are key drivers of mitochondrial dysfunction and cellular energy failure across multiple indications, including acute (AKI) and chronic kidney diseases (CKD), as well as metabolic disorders.
By inhibiting ACMSD, selectively and highly expressed in tubular epithelial cells, TESP‑0401 restores NAD⁺ levels in the kidney, thereby supporting mitochondrial function and cellular energetics. This mechanism targets a fundamental driver of disease progression, enabling recovery of essential cellular processes and improving cellular homeostasis under conditions of stress and injury.
Importantly, TESP‑0401 not only confers protection in AKI but also extends its therapeutic potential to CKD, where mitochondrial dysfunction and tubular injury contribute to progressive loss of renal function and fibrosis. By targeting NAD⁺ metabolism, TESP‑0401 represents a novel and differentiated approach to prevent tubular damage, reduce fibrosis, and preserve kidney function in renal diseases.
About Tes Pharma
Tes Pharma, a biopharmaceutical company focused on developing first-in-class therapeutics for high unmet medical needs in renal diseases. The company’s lead compound TESP-0401 demonstrated significant effect in models of acute (AKI) and chronic kidney diseases (CKD). TESP-0401 is entering first-in human studies in 2026 for prevention of delayed graft function in kidney transplantation. Tes Pharma pipeline includes also a series of compounds for CKD and renal fibrosis in different stages of preclinical development.
For more information, please visit www.tespharma.com or connect with the Company on LinkedIn
For further information, please contact:
Sara Malincarne
smalincarne@tespharma.com